Search Results
Sep 01, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing
More news about: Karyopharm Therapeutics Inc.
Aug 31, 2026, 07:30 ET Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
(2023)About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Aug 10, 2026, 07:30 ET Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing
More news about: Karyopharm Therapeutics Inc.
Aug 03, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:06 ET Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
(2023)About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
About XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology
More news about: Karyopharm Therapeutics Inc.
Jul 28, 2026, 08:00 ET AI Back-end Switch Sales to Approach $1 Trillion over the Next Five Years, According to Dell'Oro Group
pace of adoption and shipment growth is expected to accelerate further with the transition to 3.2 Tbps.Advanced pluggables, XPO, NPO, and CPO will coexist, with XPO and NPO gaining earlier momentum and CPO ramping up over time as the technology and supply chain mature.Despite Ethernet
More news about: Dell'Oro Group
Jul 16, 2026, 16:17 ET Monk Launches Cash Application 2.0, Automating 80% of Payment Matching with a Fully Auditable AI Engine
organizations have implemented or are planning to implement AI, yet only 7% report a high or very high impact.* Speaking at the Gartner Finance Symposium/Xpo 2026 in London, Ash Mehta, Sr Director Analyst in the Gartner Finance practice, said: "Organizations that succeed with AI are not necessarily smarter,
More news about: Monk
Jul 01, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential
More news about: Karyopharm Therapeutics Inc.
Jun 26, 2026, 10:10 ET Anivive Lifesciences Announces FDA Approval of Laverdia®, the First Oral Treatment of Its Kind for Canine Lymphoma
recruit dogs for the nationwide pivotal study, contributing approximately 40% of enrollment, accelerating the path to approval.Laverdia works as an XPO1 inhibitor by selectively inhibiting nuclear export proteins involved in cancer cell survival, a mechanism pioneered in veterinary oncology by Anivive's
More news about: Anivive Lifesciences Inc.
Jun 24, 2026, 15:15 ET Financial Performance Analysis of the Ten Largest U.S. Trucking Companies, according to Demotech, Inc.
ten companies selected were the largest by market capitalization:Old Dominion Freight Line Inc.JB Hunt Transport Services Inc.XPO Logistics Inc.Saia Inc.Knight-Swift Transportation Holdings Inc.RXO Inc.Schneider National Inc.ArcBest Corp.Werner
More news about: Demotech, Inc.
Jun 17, 2026, 14:25 ET OTR Transportation Appoints Kyle Ingraham as Chief Executive Officer
Services, where he guided the company through significant commercial and operational transformation, and in senior leadership positions at AFC Logistics and XPO Logistics, where he scaled revenue, built organizational infrastructure, and drove sustained profitability improvements across multiple markets."Kyle
More news about: OTR Transportation LLC
Jun 15, 2026, 17:58 ET 美納里尼集團於 2026 年歐洲血液學協會 (EHA) 年會公佈 Selinexor 聯合 Ruxolitinib 治療骨髓纖維化的第 3 期 SENTRY 試驗數據
亦於美國、歐洲及其他全球地區銷售 Tagraxofusp-erzs。這是一種針對 CD123 的新型標靶治療，適用於治療母細胞性漿細胞樣樹突細胞腫瘤 (BPDCN) 患者。BPDCN 是一種侵襲性血液系統惡性腫瘤。 此外，Stemline 亦於歐洲銷售 Selinexor。Selinexor 是一種用於治療多發性骨髓瘤的 XPO1 抑制劑。 公司目前亦正分別就 Elacestrant 及 Tagraxofusp 進行多項擴展適應症研究，涵蓋乳癌及血液系統惡性腫瘤等範疇；同時，公司亦擁有龐大的臨床研發管線，多款候選藥物正處於不同開發階段，涵蓋多種實體腫瘤及血液系統惡性腫瘤。參考資料1.
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:44 ET Le Groupe Menarini présente les résultats de l'essai clinique SENTRY de phase III sur l'association selinexor-ruxolitinib dans le traitement de la myélofibrose lors du congrès 2026 de l'Association européenne d'hématologie (EHA)
cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline commercialise en Europe le sélinexor, un inhibiteur de XPO1 pour le traitement du myélome multiple. La société mène également de multiples études d'extension d'étiquette avec l'élacestrant et le tagraxofusp dans
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:40 ET El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis
cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa en Europa selinexor, un inhibidor de XPO1 para el mieloma múltiple. La compañía también está llevando a cabo varios estudios de ampliación de indicaciones con elacestrant y tagraxofusp para
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:00 ET Il Gruppo Menarini presenta i dati dello studio di fase 3 SENTRY su selinexor più ruxolitinib nella mielofibrosi in occasione del Congresso 2026 dell'Associazione Europea di Ematologia (EHA)
ematologico aggressivo, negli Stati Uniti, in Europa e in altre regioni del mondo. Inoltre, Stemline commercializza in Europa selinexor, un inibitore di XPO1 per il mieloma multiplo. L'azienda sta inoltre conducendo diversi studi di estensione dell'indicazione con elacestrant e tagraxofusp, rispettivamente
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:17 ET 메나리니 그룹, 2026 유럽혈액학회(EHA) 학술대회에서 골수섬유증 대상 셀리넥서 및 룩소리티닙 병용요법의 제3상 SENTRY 시험 데이터 발표
지역에서 공격적인 혈액암인 모구성 형질 세포성 수지 세포 신생물(BPDCN) 환자를 대상으로 CD123을 표적으로 하는 새로운 표적 치료제 타그락소푸스프-erzs(tagraxofusp-erzs)를 상업화하고 있다. 또한 스템라인은 유럽에서 다발성 골수종 치료를 위한 XPO1 억제제인 셀리넥서를 상업화하고 있다. 이 회사는 유방암 및 혈액암 적응증에서 각각 엘라세스트란트와 타그락소푸스프의 여러 적응증 확대 시험도 진행하고 있으며, 다수의 고형암 및 혈액암을 대상으로 다양한 개발 단계의 추가 신약 후보물질로 구성된 광범위한 임상 파이프라인을
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
(BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y otras regiones del mundo. Además, Stemline comercializa selinexor, un inhibidor de XPO1 para el mieloma múltiple, en Europa. La empresa también está llevando a cabo múltiples estudios de expansión de etiquetas con elacestrant y tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
câncer hematológico agressivo, nos Estados Unidos, Europa e outras regiões globais. Além disso, a Stemline comercializa o selinexor, um inibidor de XPO1 para mieloma múltiplo, na Europa. A empresa também está conduzindo vários estudos de expansão de rótulo com elacestranto e tagraxofusp em indicações
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
hämatologischen Krebserkrankung, in den Vereinigten Staaten, Europa und anderen globalen Regionen. Darüber hinaus vertreibt Stemline in Europa Selinexor, einen XPO1-Inhibitor zur Behandlung des multiplen Myeloms. Das Unternehmen führt außerdem mehrere Studien zur Erweiterung der Indikation mit Elacestrant und Tagraxofusp
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
(BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 10, 2026, 04:15 ET CameraMatics raises up to €49 million of new funding and partial realisation of investment in CameraMatics
Amsterdam, Barcelona and the United States.Recent enterprise contract wins include major organisations such as Royal Mail, Calor Gas, Wolseley, XPO and DFDS, while in the US, the company has expanded significantly through deployments with NASDAQ-listed Installed Building Products, which operates
More news about: Mindflair Plc
Jun 08, 2026, 10:00 ET Reply at Gartner® Marketing Symposium/Xpo™ 2026, Sharing Expertise in Applying AI to Customer Experience and Marketing Operations
Western Europe - Reply will engage with clients and partners at Gartner Marketing Symposium/Xpo 2026 to discuss ongoing initiatives and applied AI use cases.Gartner and Marketing Symposium/Xpo are trademarks of Gartner, Inc. and/or its affiliates.ReplyReply [EXM, STAR:
More news about: Reply
Jun 03, 2026, 16:15 ET Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential
More news about: Karyopharm Therapeutics Inc.